Ping An Biomedical Co., Ltd. (PASW) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ping An Biomedical Co., Ltd. stock (PASW) is currently trading at $0.15. Ping An Biomedical Co., Ltd. PS ratio (Price-to-Sales) is 0.51. WallStSmart rates PASW as Sell.
- PASW PE ratio analysis and historical PE chart
- PASW PS ratio (Price-to-Sales) history and trend
- PASW intrinsic value — DCF, Graham Number, EPV models
- PASW stock price prediction 2025 2026 2027 2028 2029 2030
- PASW fair value vs current price
- PASW insider transactions and insider buying
- Is PASW undervalued or overvalued?
- Ping An Biomedical Co., Ltd. financial analysis — revenue, earnings, cash flow
- PASW Piotroski F-Score and Altman Z-Score
- PASW analyst price target and Smart Rating
Ping An Biomedical Co.,
📊 No data available
Try selecting a different time range
Smart Analysis
Ping An Biomedical Co., Ltd. (PASW) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Ping An Biomedical Co., Ltd. (PASW) Key Strengths (1)
Paying less than $1 for every $1 of annual revenue
Supporting Valuation Data
Ping An Biomedical Co., Ltd. (PASW) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -62.00%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 0.23%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Ping An Biomedical Co., Ltd. (PASW) Detailed Analysis Report
Overall Assessment
This company scores 24/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales. Valuation metrics including Price/Sales (0.51) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Book (2.77) suggest expensive pricing. Growth concerns include Revenue Growth at -62.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -67.40%, Operating Margin at -69.60%, Profit Margin at -37.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -67.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -62.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PASW Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PASW's Price-to-Sales ratio of 0.51x sits near its historical average of 0.52x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 5% below its historical high of 0.54x set in Mar 2026, and 1% above its historical low of 0.51x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ping An Biomedical Co., Ltd. (PASW) · CONSUMER CYCLICAL › TEXTILE MANUFACTURING
The Big Picture
Ping An Biomedical Co., Ltd. is in a turnaround phase, with management focused on restoring profitability. Revenue reached 34M with 62% decline year-over-year. The company is currently unprofitable, posting a -37.6% profit margin.
Key Findings
Revenue contracted 62% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -37.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor TEXTILE MANUFACTURING industry trends, competitive moves, and regulatory changes that could impact Ping An Biomedical Co., Ltd..
Bottom Line
Ping An Biomedical Co., Ltd. is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:02:20 AM
About Ping An Biomedical Co., Ltd.(PASW)
NASDAQ
CONSUMER CYCLICAL
TEXTILE MANUFACTURING
USA
Ping An Biomedical Co., Ltd., provides supply chain management services in the apparel industry in China.